Effect and mechanism of protease inhibitor oprozomib on doxorubicin sensitivity of hepatocellular carcinoma cells

• Egile Nagusiak: Feng Qi (Egilea), Sheng Zheng (Egilea), Lu Hou (Egilea), XinNian Fu (Egilea), XinXin Wang (Egilea), ZhiPeng Fu (Egilea), Juan Yang (Egilea)
• Formatua: Liburua
• Argitaratua: Polskie Towarzystwo Farmaceutyczne, 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

This study was to examine the impact of Oprozomib (OPZ), an oral second-generation proteasome inhibitor, on the sensitivity of hepatocellular carcinoma (HCC) cells to doxorubicin (DOX), a commonly used chemotherapy drug for the treatment of HCC. HCC cells were incubated with OPZ or DOX. Cell prolife...